SCHEMBL2834183

SCHEMBL2834183

CCCn1c(CN2CCN(C(C)(C)C)CC2)c(C(=O)O)c2cccc(F)c2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR2 P21452 1/20 0.38
TACR3 P29371 1/20 0.38
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 3/20 0.34
PLK1 P53350 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GNRHR P30968 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
OPRM1 P35372 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
GAA P10253 1/20 0.32
SLC6A4 P31645 3/20 0.32
HTR2A P28223 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2149098 0.89 CNR2 (0.40) ALDH1A1KDM4EPLK1NPC1POLB
SCHEMBL2149708 0.86 TACR3 (0.37) TACR2TACR3ALDH1A1PLK1NPC1
SCHEMBL2676869 0.83 TACR2 (0.40) TACR2TACR3ALDH1A1KDM4EMEN1
SCHEMBL3345785 0.83 TACR2 (0.38) TACR2TACR3
SCHEMBL2148916 0.80 BDKRB1 (0.40) LMNAPOLBMEN1KMT2AHTT
SCHEMBL2154007 0.80 CYP2C9 (0.41) TACR2TACR3ALDH1A1NPC1LMNA
SCHEMBL2830796 0.79 CNR2 (0.39) ALDH1A1KDM4EPLK1NPC1LMNA
SCHEMBL1550220 0.78 TACR2 (0.39) TACR2TACR3ALDH1A1KDM4ERAB9A
SCHEMBL2148998 0.76 ADORA2B (0.34) TACR2TACR3ALDH1A1KDM4EPLK1
SCHEMBL2831862 0.76 CNR2 (0.46) ALDH1A1KDM4EPLK1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 TACR2 39/4885TACR3 34/4885ALDH1A1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.